REGN - Spark Newswire

4 minute read

Biotech Investors: August’s Key PDUFA Catalysts You Must Know

Today, 7:55 AM

Regulatory decisions have yet to pick up pace this year. July’s calendar was light, but the good news was that most decisions turned out to be positive. That said, none of the drugs approved during the month were new molecular entities, underlining a lack of innovation going on in the sector.

ACAD

1 minute read

Regeneron’s Price Target Cut On Dim Prospects For Its Flagship Eye Product

By Vandana Singh

Today, 7:55 AM

SVB has cut the price target from $738 to $630 and downgraded from Outperform to Market Perform to reflect Regeneron Pharmaceutical Inc’s (NASDAQ:REGN)…

REGN

10 minute read

Benzinga’s Top Ratings Upgrades, Downgrades For July 25, 2022

By Benzinga Insights

Today, 7:55 AM

Upgrades

ALLY

1 minute read

SVB Leerink Downgrades Regeneron Pharmaceuticals to Market Perform, Lowers Price Target to $630

By Benzinga Newsdesk

Today, 7:55 AM

SVB Leerink analyst David Risinger downgrades Regeneron Pharmaceuticals (NASDAQ:REGN) from Outperform to Market Perform and lowers the price target from $738 to $630.

REGN

2 minute read

Analyst Ratings

Where Regeneron Pharmaceuticals Stands With Analysts

By Benzinga Insights

Today, 7:55 AM

Over the past 3 months, 10 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

REGN

1 minute read

Regeneron-Sanofi’s Dupixent Hits Primary Goal In Esophagitis Patients Below 11 Years

By Vandana Singh

Today, 7:55 AM

Regeneron Pharmaceuticals Inc (NASDAQ:REGN) and Sanofi SA’s (NASDAQ:SNY) Phase 3 trial of Dupixent (dupilumab) in children aged 1 to 11 years…

REGN

4 minute read

News

Sanofi, Regeneron Announced Dupixent Phase 3 Trial in Children 1 to 11 Years of Age With Eosinophilic Esophagitis Met Its Primary Endpoint of Histological Disease Remission at 16 Weeks With Both Higher and Lower Dose Weight-tiered Regimens

By Charles Gross

Today, 7:55 AM

A Phase 3 trial assessing the investigational use of Dupixent® (dupilumab) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) met its primary endpoint of histological disease remission at 16 weeks with both higher and lower dose weight-tiered regimens. There are no approved treatments for children with EoE under 12 years of age. Naimish Patel, M.D.

REGN

3 minute read

The Daily Biotech Pulse: AstraZeneca’s COVID-19 Vaccine As Effective As mRNA Shots, Humanigen’s Lenzilumab Disappoints In COVID-19 Study, Positive Preclinical Data From Hoth’s Alzheimer’s Program

By Vandana Singh

Today, 7:55 AM

Here's a roundup of top developments in the biotech space over the last 24 hours:

AGIO

2 minute read

What Are Whales Doing With Regeneron Pharmaceuticals

By Benzinga Insights

Today, 7:55 AM

A whale with a lot of money to spend has taken a noticeably bearish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 52 strange trades.

REGN

4 minute read

Attention Biotech Investors: Mark Your Calendar For These July PDUFA Dates

By Shanthi Rexaline

Today, 7:55 AM

The biotech sector is poised to end June on a positive note, despite largely disappointing regulatory decisions scheduled during the month, thanks to a reversal in broader market sentiment.

ACER

Feed Symbols: REGN